Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease

Author:

Rymer Jennifer A.1ORCID,Mulder Hillary2,Narcisse Dennis I.1ORCID,Rockhold Frank2ORCID,Hiatt William R.3ORCID,Fowkes F. Gerry4,Baumgartner Iris5,Berger Jeffrey S.6ORCID,Katona Brian G.7,Mahaffey Kenneth8,Norgren Lars9,Blomster Juuso I.10,Jones W. Schuyler1,Patel Manesh R.1

Affiliation:

1. Division of Cardiology, Duke University Medical Center, Durham, NC (J.A.R., D.I.N., W.S.J., M.R.P.).

2. Duke Clinical Research Institute, Durham, NC (H.M., F.R.).

3. University of Colorado School of Medicine, CPC Clinical Research, Aurora (W.R.H.).

4. Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, United Kingdom (F.G.F).

5. Swiss Cardiovascular Center, Bern, Switzerland (I.B.).

6. Division of Cardiology, NYU Langone Health, New York, NY (J.S.B.).

7. AstraZeneca, Gaithersburg, MD (B.G.K.).

8. Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.M.).

9. Faculty of Medicine and Health, Orebro University, Sweden (L.N.).

10. University of Turku, Finland (J.I.B.).

Abstract

Background: Patients with peripheral artery disease have a high risk of future cardiovascular disease events and mortality. Little is known about the changes in symptom classification over time in patients with peripheral artery disease and the association of changes in symptom classification with subsequent cardiovascular disease events. Methods: In this analysis of the EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease), we examined the changes in Rutherford classification (RC) of patients over 12 months. We examined the baseline characteristics of patients by change in symptom classification at 12 months (improved=decreased RC, no change, or worsened=increased RC), and the association between changes in symptom classification (RC) at 12 months and subsequent cardiovascular disease events. Results: Among 12 759 patients, 3240 (25%) were classified as improved by RC at 12 months, 8132 (64%) as no change, and 1387 (11%) as worsened. At 12 months, many patients who were asymptomatic or had mild/moderate claudication at enrollment had no change in symptom classification over 12 months (73.7% and 70.9%). Patients who worsened over 12 months were more likely to have comorbidities (diabetes mellitus and prior myocardial infarction) and more events (myocardial infarction, amputation, and major bleeding) by 12 months postrandomization, all P <0.001. Worsened symptom classification over 12 months was associated with increased risk of all-cause death (adjusted hazard ratio, 1.29 [95% CI, 1.03–1.62]), major amputation (adjusted hazard ratio, 4.12 [95% CI, 2.46–6.88]), and a composite of cardiovascular death, myocardial infarction, or stroke (adjusted hazard ratio, 1.30 [95% CI, 1.05–1.62]), all P <0.05 after 12 months postrandomization. Conclusions: Patients with comorbidities and prior history of cardiovascular disease events at baseline and within the first 12 months of the trial were more likely to have worsened symptom classification at 12 months. Worsening symptom classification over 12 months was associated subsequently with an increased risk of all-cause death, amputation, and a composite of cardiovascular death, myocardial infarction, or stroke. Graphic Abstract: A graphic abstract is available for this article.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3